ArticleCardiovascular diabetology2018
Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
Article in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The potential of precision diabetology for type 2 diabetes treatment-evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials.Acta diabetologica · 2025Pooled it
- Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data.Journal of nephrology · 2024Pooled it
- Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.Cardiovascular diabetology · 2019Trial
- CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.Cardiovascular diabetology · 2026Article
- CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes.Cardiovascular diabetology · 2025Article
- CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.Cardiovascular diabetology · 2024Article
- CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.Cardiovascular diabetology · 2023Article
- Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.Cardiovascular diabetology · 2022Article
- Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care.Diabetes/metabolism research and reviews · 2021Review
- Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.Cardiovascular diabetology · 2021Article
- Report from the 5th cardiovascular outcome trial (CVOT) summit.Cardiovascular diabetology · 2020Article
- Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.The American journal of cardiology · 2019Review
- Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?BMJ open diabetes research & care · 2019Article
- Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.Cardiovascular diabetology · 2019Article
- Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.Cardiovascular diabetology · 2019Article
- Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.Cardiovascular diabetology · 2019Review
- PDM-ProValue meets cardiovascular outcome trials in diabetes.Cardiovascular diabetology · 2019Article
- Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes.Journal of pharmaceutical policy and practice · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 3rd Cardiovascular Outcome Trial Summit of the Diabetes & Cardiovascular Disease EASD Study Group was held on the 26-27 October 2017 in Munich. As in 2015 and 2016, this summit was organised in light of recently completed and published CVOTs on diabetes, aiming to serve as a reference meeting for in-depth discussions on the topic. Amongst others, the CVOTs EXSCEL, DEVOTE, the CANVAS program and the ACE-trial, which released primary outcome results in 2017, were discussed. Trial implications for diabetes management and recent perspectives of diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners were highlighted. The clinical relevance of cardiovascular outcome trials and its implications regarding reimbursement were compared with real-world studies. The 4th Cardiovascular Outcome Trial Summit will be held in Munich 25-26 October 2018 ( http://www.dcvd.org ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.